Details for 2020811814

Up to date per 02.04.2026

Actions

Title / Product Name

KOMBINATION AUS EINEM PD-1-ANTAGONISTEN, EINEM VEGFR/FGFR/RET-TYROSINKINASEINHIBITOR UND EINEM CBP/BETA-CATENIN-INHIBITOR ZUM BEHANDELN VON KREBS

Status

Granted/Registered

Protection Type

European Patent

(AT-) Application Number

2020811814

EP Publication Number

4051278

E-Number

1867884

Language

PCT Number

US20057650

Publication Date

07.09.2022 A

17.12.2025 B1

Registration Date

17.12.2025

AT Publication Date

15.01.2026

Application Date

28.10.2020

Registration Number

Priorities

29.10.2019

201962927334 P

29.10.2019

201962927576 P

IPC

A61K 31/47 20060101AFI20210508BHEP

Maximum Duration of Protection

28.10.2040

Owner

Eisai R&D Management Co., Ltd.6-10 Koishikawa, 4-Chome Bunkyo-Ku Tokyo 112-8088JP

Merck Sharp & Dohme LLC126 East Lincoln Avenue Rahway, New Jersey 07065US

MSD International GmbHWeystrasse 20 6006 LuzernCH

Representative

No representatives present

Inventor

OZAWA, YoichiC/O Eisai Co., Ltd. Tsukuba Research Laboratories, 5-1-3 Tokodai Tsukuba-shi, Ibaraki 300-2635JP

FUNAHASHI, YasuhiroC/O Eisai Co., Ltd. Tsukuba Research Laboratories, 5-1-3 Tokodai Tsukuba-shi, Ibaraki 300-2635JP

KATO, YuC/O Eisai Co., Ltd. Tsukuba Research Laboratories, 5-1-3 Tokodai Tsukuba-shi, Ibaraki 300-2635JP

Information about Fees